| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Type-2 angiotensin II receptor |
|---|
| Ligand | BDBM50011977 |
|---|
| Substrate/Competitor | n/a |
|---|
| Ki | >10000±n/a nM |
|---|
| Comments | PDSP_1718 |
|---|
| Citation |  Keiser, JA; Ryan, MJ; Panek, RL; Hodges, JC; Sircar, I Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist. J Pharmacol Exp Ther272:963-9 (1995) [PubMed] |
|---|
| More Info.: | Get all data from this article |
|---|
| |
| Type-2 angiotensin II receptor |
|---|
| Name: | Type-2 angiotensin II receptor |
|---|
| Synonyms: | AGTR2_RAT | AT2 | Agtr2 | Angiotensin II AT2 | Angiotensin II receptor | Angiotensin II type 2 (AT-2) receptor | Type-2 angiotensin II receptor |
|---|
| Type: | Enzyme Catalytic Domain |
|---|
| Mol. Mass.: | 41346.62 |
|---|
| Organism: | RAT |
|---|
| Description: | Angiotensin II AT2 0 0::P35351 |
|---|
| Residue: | 363 |
|---|
| Sequence: | MKDNFSFAATSRNITSSLPFDNLNATGTNESAFNCSHKPADKHLEAIPVLYYMIFVIGFA
VNIVVVSLFCCQKGPKKVSSIYIFNLAVADLLLLATLPLWATYYSYRYDWLFGPVMCKVF
GSFLTLNMFASIFFITCMSVDRYQSVIYPFLSQRRNPWQASYVVPLVWCMACLSSLPTFY
FRDVRTIEYLGVNACIMAFPPEKYAQWSAGIALMKNILGFIIPLIFIATCYFGIRKHLLK
TNSYGKNRITRDQVLKMAAAVVLAFIICWLPFHVLTFLDALTWMGIINSCEVIAVIDLAL
PFAILLGFTNSCVNPFLYCFVGNRFQQKLRSVFRVPITWLQGKRETMSCRKSSSLREMDT
FVS
|
|
|
|---|
| BDBM50011977 |
|---|
| n/a |
|---|
| Name | BDBM50011977 |
|---|
| Synonyms: | (E)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid | (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid | (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid | 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid | CHEMBL813 | EPROSARTAN |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C23H24N2O4S |
|---|
| Mol. Mass. | 424.513 |
|---|
| SMILES | CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O |
|---|
| Structure | 
|
|---|
Search and Browse
